A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
Primary Objective:
To assess the safety and tolerability of GZ402668 after a single subcutaneous (SC) dose in
men and women with progressive multiple sclerosis.
Secondary Objectives:
To assess in men and women with progressive multiple sclerosis:
- The pharmacokinetic (PK) parameters of GZ402668 after a single SC dose.
- The pharmacodynamic (PD) response to GZ402668 after a single SC dose.